A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

NCT01544348 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

295

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Asthma
Atopic Dermatitis
Allergic Rhinitis
Healthy Volunteers

Interventions

OTHER: Placebo
BIOLOGICAL: Omalizumab
BIOLOGICAL: MEDI4212 5 mg Subcutaneous
BIOLOGICAL: MEDI4212 15 mg Subcutaneous
BIOLOGICAL: MEDI4212 60 mg Subcutaneous
BIOLOGICAL: MEDI4212 150 mg Subcutaneous
BIOLOGICAL: MEDI4212 300 mg Subcutaneous
BIOLOGICAL: MEDI4212 300 mg Intravenous

Sponsor

MedImmune LLC